Company Overview and News

 
Celyad: Why Did It Go Down Recently?

2017-11-15 seekingalpha
In this piece, Dr Maiya follows up on his coverage on Celyad (CYAD), and discusses some data released from the THINK trial.
Upvote Downvote

 
Edison Issues ADR Update on Celyad (CYAD)

2017-10-30 accesswire
LONDON, UK / ACCESSWIRE / October 30, 2017 / Celyad SA (NASDAQ: CYAD) has reported a complete morphological leukemia-free status (MFLS) response in acute myeloid leukemia (AML) in the NKR CAR T-cell THINK study. Spontaneous remission in refractory/relapsed AML is extremely rare, so this is a significant result. Importantly, the response was achieved with no toxic preconditioning. CYAD-01 has shown limited toxicities to date.
Upvote Downvote

1
Will Biotech Continue To Boom?

2017-10-12 seekingalpha
Avisol Capital Partners joins the Roundtable to discuss their approach to biotech valuations and the warning signs they look for in the stocks they research.
Upvote Downvote

 
3 Things In Biotech You Should Learn Today: October 4, 2017

2017-10-04 seekingalpha
Welcome to another edition of "3 Things In Biotech You Should Learn Today," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotechnology research.
Upvote Downvote

 
Celyad: Some Questions For Management

2017-07-07 seekingalpha
I recently covered Celyad (CYAD), a small Belgian company developing CAR-T therapy for solid tumors, and I have a few follow up questions. Some of these needs to be answered by management, but some I could probably answer.
Upvote Downvote

 
Gilead And CAR-T Of Solid Tumors: The Next Revolution In Cancer Therapeutics

2017-06-28 seekingalpha
However, the onco space is one that can offer a good replacement option for its HCV franchise.
Upvote Downvote

 
Buy Celyad And Get In On The CAR-T Space In Solid Tumors: Medicine's Next Frontier

2017-06-27 seekingalpha
In the entire field of oncology, perhaps the most disruptive ongoing revolution is the application of Chimeric Antigen Receptor - T Cells or (CAR-T) to cancer immunotherapy. In this therapy, engineered T-cells that express a specific tumor antigen binding domain called Chimeric Antigen Receptor is infused into the patient. As the construct binds to its target domain, the T-cell is activated and attacks the cancer cell with great specificity.
Upvote Downvote

 
TiGenix: This Stem Cell Pioneer Is Up 40% Since IPO With More Upside To Come

2017-06-27 seekingalpha
The biotech has signed a $400+ million deal with big pharma Takeda for its lead asset, Cx601, which should be approved in Europe before YE2017
Upvote Downvote

 
Myelodysplastic Syndrome Pipeline Therapeutic Drugs and Companies Review H1 2017 Research Report Available at RnRMarketResearch

2017-06-21 prnewswire
RnRMarketResearch.com adds "Myelodysplastic Syndrome Pipeline Review H1 2017" therapeutic market research report provides an overview of the Myelodysplastic Syndrome's therapeutic pipeline.
Upvote Downvote

 
3 Biotech Stocks That More than Doubled Year to Date

2017-06-19 zacks
We are almost half way through 2017 and the biotech sector, which had a rough and challenging 2016, has been showing signs of recovery despite some ups and downs. Year-to-date (YTD), the NASDAQ Biotechnology Index is up 10.4% providing a glimmer of hope to biotech investors who saw the Index sliding 19.1% in 2016.      While the drug pricing issue remains a headline risk this year as well, confidence in the sector has been boosted by strong results, R&D success and innovation, FDA approvals, ramp up in new product sales and continued strong performance from legacy products.
Upvote Downvote

 
Novartis: Follow The (Belgian) Yellow Brick Road

2017-05-18 seekingalpha
Novartis will release the interim data from the JULIET trial, during the International Conference on Malignant Lymphoma.
Upvote Downvote

 
Pipeline of Congestive Heart Failure Market Review Research for H1 2017 - Reports and Reports

2017-03-22 prnewswire
ReportsnReports.com adds "Congestive Heart Failure (Heart Failure) - Pipeline Review, H1 2017" to its store providing comprehensive information on the therapeutics under development for Congestive Heart Failure (Heart Failure), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
Upvote Downvote

 
U.S. Money and Local Talent the Growth Plan for European Biotech - Bloomberg

2017-01-09 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
Upvote Downvote

 
Bayer And Versant's Big Bet On Stem Cells

2016-12-14 seekingalpha
Repeated failure has not dissuaded the sector from chasing the hypothesis that cardiac tissue can be regenerated with stem cell therapy. The latest players are Bayer (OTCPK:BAYZF, OTCPK:BAYRY) and Versant Ventures, which invested $225m in Bluerock Therapeutics, a business that will focus on cardiovascular disease as its lead programme.
Upvote Downvote

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...